Federal Government-Funded Study Fails to Recognize Value of Vitamin D
A brutal war is being waged whose outcome will determine how long humans live and whether our health care system economically collapses.
On one side are the earnings projections of the entrenched medical establishment. These profits are contingent on large numbers of aging Americans contracting cancers, heart attacks, strokes, viral infections and other ailments.
On the other side are irrefutable scientific findings showing the incidence of these deadly diseases can be slashed if Americans increase their intake of vitamin D.
If too many Americans optimize their vitamin D blood status, the medical establishment will sustain huge economic losses as incident rates of degenerative disease rapidly plummet.
In order to protect their outlandish profits, the medical establishment will do whatever it takes to mislead and frighten the public away from higher supplemental vitamin D usage.
The medical establishment has a stranglehold over our federal government, academia, and a large segment of the media. As a result, what you are led to believe is tightly controlled by those whose financial interests are dependent on millions of Americans each year contracting degenerative diseases.
In response to overwhelming documentation that higher levels of vitamin D protect against virtually every disease, the federal government commissioned the Institute of Medicine to assemble a committee of experts to formally evaluate the data. The experts on this panel have ties in one way or another to the vested interests of the entrenched medical establishment.
On November 30, 2010, the Institute of Medicine (IOM) issued a 1,016 page report that concludes that most people in the U.S. and Canada — from age 1 to age 70 — need to consume no more than 600 international units (IU) of vitamin D a day to maintain health. The IOM report mandated those levels as the "recommended dietary allowance" for vitamin D.
This new recommendation is triple the previous recommended daily amount of 200 IU that the Institute of Medicine established in 1997. Just as the 200 IU dose of vitamin D was woefully inadequate based on data existing in 1997, so is the ridiculous new recommended daily amount of only 600 IU of vitamin D.
How do we know this? The Life Extension Foundation conducted the largest analysis of vitamin D blood tests ever on a group of dedicated supplement users. The typical doses of vitamin D that these individuals used were between 800 IU and 2600 IU a day. The findings showed that 85% of these supplement users had insufficient vitamin D, defined as less than 50 ng/mL of 25-hydroxyvitamin D.
Virtually all who follow the recommendations of the federal government-funded IOM study (to take only 600 IU a day of vitamin D) will have insufficient or deficient vitamin D blood levels.
The IOM report recognizes this and comes to an even more absurd conclusion that most Americans need to maintain blood 25-hydroxyvitamin D levels of a paltry 20 ng/mL. Those who rely on this horribly flawed IOM report are condemned to suffer horrifically high rates of virtually every known disease, thus ensuring the rosy profit projections of the entrenched medical establishment.
The IOM’s recommendations are far below the 5,000–8,000 IU per day (and higher) of supplemental vitamin D required to generate 25-hydroxyvitamin D blood levels in the range of 50–80 ng/ml, shown to be optimal based upon a variety of peer-reviewed, published scientific studies.1-2
Furthermore, the IOM recommends 4,000 IU daily of vitamin D as an upper threshold level for safety despite the fact that in their report the lowest dose of vitamin D cited as being toxic for adults is 30,000–60,000 IU daily for up to 7.5 years,1 and the lowest blood level of 25-hydroxyvitamin D cited as being toxic for adults in their report is 145 ng/mL.2
Despite the plethora of evidence highlighting the association between low 25-hydroxy vitamin D levels and various diseases including multiple types of cancer,3,4,5 cardiovascular disease,6,7 diabetes,8 and depression,9 the IOM failed to acknowledge the important role of vitamin D in areas other than bone health in their report.
The alarming lack of comprehension exhibited by the IOM in considering the extra-skeletal actions of vitamin D is exemplified by the concluding remarks of the November 30th report:
The Life Extension Foundation has undertaken a thorough review and analysis of the Institute of Medicine report as well as the existing peer-reviewed literature on vitamin D.
The findings of this comprehensive evaluation immediately follow.
Flawed Studies Mislead Public about Pancreatic Cancer and Vitamin D
Pancreatic cancer is ranked fifth among cancer-related deaths worldwide with a 5-year survival rate of less than 5%. Currently, surgery is the only effective therapy. However, most patients are diagnosed in the late stage and are not suitable for receiving curative surgery. Moreover, pancreatic cancer doesn't respond well to traditional chemotherapy and radiotherapy, leaving little effective treatment for advanced pancreatic cancer cases.
The biologically active form of vitamin D was originally identified during studies of calcium and bone metabolism though it is now recognized that it exerts biological effects in almost every tissue in the body. Abundant evidence has shown that biologically active vitamin D has anti-proliferative, apoptotic, pro-differentiation and anti-angiogensis effects in many types of cancer cells in vivo and in vitro, including breast, prostate, and colon. Similarly, the anti-tumor growth effect of activated vitamin D on pancreatic cells has been demonstrated.10
The IOM report, however, questions whether higher vitamin D blood levels increase pancreatic cancer rates. One study IOM relied on was of Finnish male cigarette smokers. The study showed that those with 25-hydroxyvitamin D levels above 26.2 ng/mL sixteen years prior to diagnosis were three times more likely to contract pancreatic cancer than those with 25-hydroxyvitamin D below 12.8 ng/mL. One problem with this analysis is that neither of these levels comes close to achieving the blood levels of 25-hydroxyvitamin D (greater than 50 ng/mL) required to provide cancer protection. A more serious problem is the testing methodology used in this study to measure 25-hydroxyvitamin blood levels was later found to be unreliable and is no longer being used. So no one knows what the 25-hydroxyvitamin blood levels really were in this group. The IOM panel members would not have known that the testing methodologies used in this study were recently discredited. We at Life Extension did because the largest blood testing lab in the U.S. (Quest) had been using it and later switched to the LabCorp methodology to avoid the issue of unreliable results. (More on this later.)
An epidemiology meta-analysis [a population-based statistical evaluation of ten different studies from the United States, Finland, and China called the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP)] examined the associations between circulating 25-hydroxyvitamin D concentrations and the risk of rarer types of cancers like pancreatic cancer. This study used a flawed statistical method to arrive at this conclusion, but the most obvious error was that it stated that those with 25-hydroxyvitamin D levels over 40 ng/mL of 25-hydroxyvitamin D were at the highest risk. Life Extension knows from its own analysis that it takes around 5,000 IU of supplemental vitamin D to achieve blood levels greater than 40 (ng/mL), and that probably NONE of the study participants evaluated ever supplemented with this much vitamin D (or took any supplements at all for that matter). Consider that individuals in Finland have minimal (or no) sun exposure, and over the majority of the time period evaluated (1974–2006), virtually no one was taking more than 200–400 IU of supplemental vitamin D a day (or none at all). Life Extension knows from our own internal analysis that 800–1600 IU daily of vitamin D3 does not yield >40 ng/mL 25-hydroxyvitamin D levels in the blood. (Young individuals in the summertime typically have 25-hydroxyvitamin D levels of >60 ng/mL, but older individuals do not efficiently synthesize vitamin D from sunlight.)
We also highly suspect this high blood level of 25-hydroxyvitamin D (>40 ng/mL) was a false reading based on faulty blood test methodologies. Not all of the blood samples were assayed in a central laboratory using a direct, competitive chemiluminescence immunoassay on the DiaSorin LIAISON platform (DiaSorin, Inc., Stillwater, Minnesota) used by LabCorp. This is a critical fact because other types of vitamin D assays, such as the HPLC dual mass spec assay used by Quest, have potential to generate inaccurate results.
Scientific data must always be interpreted in the context of the wider literature as a whole. In fact, a review of the literature strongly indicates inconsistency of the results obtained by this flawed epidemiology meta-analysis. Specifically, the vast majority of the data indicates a protective role for vitamin D and pancreatic cancer.
Greater sun exposure and vitamin D production in the skin have been associated with lower death rates for pancreatic cancer in studies in Caucasians11,12, Japanese13,14, and African American15 populations. These studies show that changes are attributable to variations in sun exposure by geographic latitude with individuals at lower latitudes having higher vitamin D status and less cancer. Other published data clearly show that risk factors for pancreatic cancer such as age, obesity, and African American ethnicity, are all associated with reduced vitamin D status.16
Two prospective clinical studies conducted in the Health Professionals Follow-up Study (HPFS) and Nurses’ Health Study (NHS) indicate that vitamin D offers protective benefit for pancreatic cancer. These massive, prospective studies evaluated cohorts of 46,771 men ages 40 to 75 years as of 1986 (the Health Professionals Follow-up Study), and 75,427 women ages 38 to 65 years as of 1984 (the Nurses’ Health Study).
The first showed that a higher predicted 25(OH) vitamin D status score was associated with a lower total cancer incidence and mortality including 51% reduced risk of pancreatic cancer (pancreatic cancer n=170, RR=0.49, 95% confidence interval (CI), 0.28–0.86 for incremental plasma 25-hydroxy vitamin D status).17
The second was a pooled analysis of the HPFS and NHS that observed higher total vitamin D intake was associated with a 41% reduced pancreatic cancer risk (n=365 cases, diet and supplemental vitamin D, ≥ 600 IU compared to < 150 IU, RR=0.59, 95% CI 0.40–0.88, p-trend=0.01).18
Greater than 90% of the men and women in the ≥ 600 IU category reported multivitamin use. In analyses stratified by cohort, significant associations for total vitamin D status were evident in the HPFS (n=178 cases, ≥ 600 IU compared to < 150 IU, RR=0.49, 95% CI 0.29–0.82, p-trend= 0.01).
Of interest, no associations were observed for vitamin D intake from foods in this second study, supporting the powerful benefits of vitamin D supplementation in helping to achieve these impressive, protective benefits for pancreatic cancer.
Another biased, methodologically flawed study published in November 2010 that received widespread mainstream media coverage concluded that dietary intake of vitamin D (≥450 IU/d vs. <150 IU/d) was associated with an increased risk of pancreatic cancer in men.19 However, careful review reveals several important facts not discussed by the media.
In this study, patients diagnosed with pancreatic cancer between 1995 and 1999 (n=532), were administered a questionnaire and asked to recall their dietary intake prior to their diagnosis of pancreatic cancer.
The accuracy of the food questionnaire that was used to determine total vitamin D intake (a 131-item semi-quantitative food frequency questionnaire) depends on the ability of the subject to recall, down to the portion size, the meals he or she ate prior to pancreatic cancer diagnosis, and further that a computer software program then generates an estimated nutrient intake.
The key point is that vitamin D intake or blood levels were not directly measured in this study. As expected, the validity of food frequency questionnaires has been questioned.20
Investigators in this study also stated that their results indicated that greater vitamin D intake (≥450 IU daily vs. <150 IU daily) was associated with increased risk for pancreatic cancer in men, but not in women, yet the researchers in this study failed to fully investigate their findings, contributing to the media’s headlines proclaiming that more than 450 IU of vitamin D daily might increase pancreatic cancer risk.
A closer look at the data that these researchers gathered reveals that as estimated vitamin D intake increased greater than 800 IU daily, pancreatic cancer risk was actually decreased.Although only a small number of samples were available for vitamin D intakes exceeding 800 IU daily (with an associated risk reduction of 19%), the researchers did offer the following statements in their conclusion.
A third study that received widespread media attention also generated unfounded concerns regarding vitamin D and pancreatic cancer.21 The authors of this highly questionable study proclaimed that a single pre-diagnostic measurement of vitamin D blood levels in male smokers was independently associated with pancreatic cancer development up to 16 years later. However, a closer look at their data reveals the true lack of predictive value of their study.
This study population consisted of 600 subjects (n = 200 for pancreatic cancer cases and n = 400 for cancer free controls) from Finland, all of whom were current smokers. Researchers assessed 25-hydroxyvitamin D blood levels between 1985 and 1988. As expected in subjects living in Finland, where exposure to sunlight is minimal during the winter months and far less pronounced during other periods of the year due to the relatively extreme northern latitude, the study subjects had, on average, extremely low levels of vitamin D (mean 20 ng/mL for cases and 18 ng/mL for controls). Furthermore, the “highest” stratified 25-hydroxyvitamin D level was identified as >26 ng/mL, woefully insufficient.
Furthermore, given that the steady state half-life of vitamin D in the blood is about three weeks and is highly susceptible to seasonal variations22, it is astonishing that these researchers felt it was acceptable to assume that vitamin D blood levels remained constant for 16 years until the patients were diagnosed with pancreatic cancer.
To assume that a single 25-hydroxy vitamin D blood level measurement in people who smoke and live in an area where sun exposure is extremely limited has anything to do with the development of pancreatic cancer 16 years later defies scientific, rational logic.
However, setting aside the obvious methodological limitations with this study, higher pre-diagnostic 25-hydroxyvitamin D levels may be observed in pancreatic patients.
In fact, using advanced techniques like immunohistochemistry, studies show that 1-alpha(OH)ase (a critical enzyme that helps generate activated vitamin D in tissue) is highly expressed in both normal and malignant pancreatic tissue. Expression of this enzyme and enzymatic activity has been detected in pancreatic tumor cell lines.
Data indicate that 25-hydroxyvitamin D3 inhibits the growth of pancreatic cell lines in a manner that correlates with the level of induction of the cyclin-dependent kinase inhibitors p21 and p27 and with the induction of cell cycle arrest at the G(1)/S checkpoint. The growth of pancreatic cancer cell lines indicates that activating Ki-Ras mutations, which occur in almost 90% of pancreatic adenocarcinomas, does not interfere with the growth-inhibitory effects of 25-hydroxy vitamin D3. The expression of 1-alpha(OH)ase in normal and malignant pancreatic tissue and the anti-proliferative effects of the prohormone in these cells indicates that 25-hydroxy vitamin D3 may offer potential therapeutic and chemopreventive options for pancreatic cancer.23 What this also means is that since pancreatic cells produce 25-hydroxyvitamin D, when someone is diagnosed with pancreatic cancer they have a large number of rapidly proliferating pancreatic cells secreting higher levels of 25-hydroxyvitamin D. So compared to healthy controls, a group of pancreatic cancer patients may as whole have higher 25-hydroxyvitamin D because they have more rapidly proliferating (malignant) pancreatic cells releasing it into the bloodstream.
Continued on Page 2 of 2